Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 54623
Encontrada(s) 5463 página(s)
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/14823
Publicación Otros (Other)

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.

  • Ruiz de Adana, Maria S
  • Alhambra-Exposito, Maria Rosa
  • Muñoz-Garach, Araceli
  • Gonzalez-Molero, Inmaculada
  • Colomo, Natalia
  • Torres-Barea, Isabel
  • Aguilar-Diosdado, Manuel
  • Carral, Florentino
  • Serrano, Manuel
  • Martinez-Brocca, Maria A
  • Duran, Ana
  • Palomares, Rafael
Objective: To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients' health-related quality of life (HRQoL), and physicians' satisfaction in patients with type 1 diabetes. Research design and methods: PLATEDIAN (Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients) (NCT03332472) was a multicenter, randomized, 6-month follow-up, open-label, parallel-group controlled study performed in patients with type 1 diabetes with suboptimal metabolic control (HbA1c <8% [<64 mmol/mol]), treated with multiple daily injections. A total of 388 patients were assessed for eligibility; 379 of them were randomized 1:1 to three face-to-face visits (control cohort [CC]) (n = 167) or the replacement of an intermediate face-to-face visit by a telemedicine visit using Diabetic (intervention cohort [IC]) (n = 163). The primary efficacy end point was the mean change of HbA1c levels from baseline to month 6. Other efficacy and safety end points were mean blood glucose, glucose variability, episodes of hypoglycemia and hyperglycemia, patient-reported outcomes, and physicians' satisfaction. Results: At month 6, the mean change in HbA1c levels was -0.04 ± 0.5% (-0.5 ± 5.8 mmol/mol) in the CC and 0.01 ± 0.6% (0.1 ± 6.0 mmol/mol) in the IC (P = 0.4941). The number of patients who achieved HbA1c <7% (<53 mmol/mol) was 73 and 78 in the CC and IC, respectively. Significant differences were not found regarding safety end points at 6 months. Changes in HRQoL between the first visit and final visit did not differ between cohorts, and, regarding fear of hypoglycemia (FH-15 score ≥28), statistically significant differences observed at baseline remained unchanged at 6 months (P < 0.05). Conclusions: The use of telemedicine in patients with type 1 diabetes with HbA1c <8% (<64 mmol/mol) provides similar efficacy and safety outcomes as face-to-face visits., Si
Recercat. Dipósit de la Recerca de Catalunya
oai:recercat.cat:2117/103444
Datos de investigación Set de datos (Dataset)

Geostandards of the Valentí Masachs Geology Museum

Geostandards du Musée de Géologie Valentí Masachs
  • Parcerisa Duocastella, David
  • Fàbrega Alsina, Carles
  • Gurenko, Andrey
  • Franke, Christine
Anàlisis geoquímiques i fotos de visu i microscòpia de les mostres que integren la col·lecció de geostandards del Museu de Geologia Valentí Masachs (UPC Manresa). Análisis geoquímicas y fotos de visu y microscopio de las muestras que integran la colección de geostandares del Museo de Geología Valentí Masachs (UPC Manresa). Geochemical analyses and hand and microscopy pictures of the samples belonging to the geostandards collection of the Valenti Masachs Geology Museum (UPC Manresa). Analyses géochimiques et photographies au microscope et visu des échantillons qui forment la collection de geostandards du Musée de Géologie Valentí Masachs (UPC Manresa)., 1
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/29939
Publicación Otros (Other)

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

  • Necchi, Andrea
  • Ramlau, Rodryg
  • Falcon-Gonzalez, Alejandro
  • Chaudhry, Arvind
  • Todenhöfer, Tilman
  • Tahbaz, Rana
  • Fontana, Elisa
  • Giannatempo, Patrizia
  • Deville, Jean-Laurent
  • Pouessel, Damien
  • Yoon, Shinkyo
  • Powles, Thomas
  • Bernat, Mathieu
  • Häckl, Manuel
  • Marszewska, Michalina
  • McKernan, Phil
  • Saulay, Mikael
  • Scaleia, Federica
  • Engelhardt, Marc
  • Loriot, Yohann
  • Siefker-Radtke, Arlene
  • Santis, Maria-de
This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA). This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1-3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5). In Substudy 2, patients with any solid tumor received atezolizumab 1200 mg every 3 weeks plus derazantinib 200 or 300 mg QD. In Substudy 3, patients with mUC harboring FGFR1-3GA received derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks. In Substudy 4, patients with FGFR inhibitor-resistant mUC harboring FGFR1-3GA received derazantinib 300 mg QD monotherapy or derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks. The ORR for Substudies 1 and 5 combined was 4/49 (8.2%, 95% confidence interval = 2.3% to 19.6%), which was based on 4 partial responses. The ORR in Substudy 4 was 1/7 (14.3%, 95% confidence interval = 0.4% to 57.9%; 1 partial response for derazantinib 300 mg monotherapy, zero for derazantinib 300 mg plus atezolizumab 1200 mg). In Substudy 2, derazantinib 300 mg plus atezolizumab 1200 mg was identified as a recommended dose for Phase 2. Only 2 patients entered Substudy 3. Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC. Clinicaltrials.gov NCT04045613, EudraCT 2019-000359-15.
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/17369
Publicación Otros (Other)

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

  • Heuser, Michael
  • Smith, B-Douglas
  • Fiedler, Walter
  • Sekeres, Mikkael-A
  • Montesinos, Pau
  • Leber, Brian
  • Merchant, Akil
  • Papayannidis, Cristina
  • Perez-Simon, Jose-A
  • Hoang, Caroline-J
  • O'Brien, Thomas
  • Ma, Weidong-Wendy
  • Zeremski, Mirjana
  • O'Connell, Ashleigh
  • Chan, Geoffrey
  • Cortes, Jorge-E
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo, n = 38; secondary acute myeloid leukemia, n = 40) or LDAC alone (de novo, n = 18; secondary acute myeloid leukemia, n = 20). At the time of analysis, 90% of patients had died, with the longest follow-up since randomization 36 months. The combination of glasdegib and LDAC conferred superior overall survival (OS) versus LDAC alone; hazard ratio (HR) 0.495; (95% confidence interval [CI] 0.325-0.752); p = 0.0004; median OS was 8.3 versus 4.3 months. Improvement in OS was consistent across cytogenetic risk groups. In a post-hoc subgroup analysis, a survival trend with glasdegib + LDAC was observed in patients with de novo acute myeloid leukemia (HR 0.720; 95% CI 0.395-1.312; p = 0.14; median OS 6.6 vs 4.3 months) and secondary acute myeloid leukemia (HR 0.287; 95% CI 0.151-0.548; p < 0.0001; median OS 9.1 vs 4.1 months). The incidence of adverse events in the glasdegib + LDAC arm decreased after 90 days' therapy: 83.7% versus 98.7% during the first 90 days. Glasdegib + LDAC versus LDAC alone continued to demonstrate superior OS in patients with acute myeloid leukemia; the clinical benefit with glasdegib + LDAC was particularly prominent in patients with secondary acute myeloid leukemia., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/16739
Publicación Otros (Other)

Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole.

  • Brignole, Michele
  • Russo, Vincenzo
  • Arabia, Francesco
  • Oliveira, Mario
  • Pedrote, Alonso
  • Aerts, Arnaud
  • Rapacciuolo, Antonio
  • Boveda, Serge
  • Deharo, Jean-Claude
  • Maglia, Giampiero
  • Nigro, Gerardo
  • Giacopelli, Daniele
  • Gargaro, Alessio
  • Tomaino, Marco
The benefit of cardiac pacing in patients with severe recurrent reflex syncope and asystole induced by tilt testing has not been established. The usefulness of tilt-table test to select candidates for cardiac pacing is controversial. We randomly assigned patients aged 40 years or older who had at least two episodes of unpredictable severe reflex syncope during the last year and a tilt-induced syncope with an asystolic pause longer than 3 s, to receive either an active (pacing ON; 63 patients) or an inactive (pacing OFF; 64 patients) dual-chamber pacemaker with closed loop stimulation (CLS). The primary endpoint was the time to first recurrence of syncope. Patients and independent outcome assessors were blinded to the assigned treatment. After a median follow-up of 11.2 months, syncope occurred in significantly fewer patients in the pacing group than in the control group [10 (16%) vs. 34 (53%); hazard ratio, 0.23; P = 0.00005]. The estimated syncope recurrence rate at 1 year was 19% (pacing) and 53% (control) and at 2 years, 22% (pacing) and 68% (control). A combined endpoint of syncope or presyncope occurred in significantly fewer patients in the pacing group [23 (37%) vs. 40 (63%); hazard ratio, 0.44; P = 0.002]. Minor device-related adverse events were reported in five patients (4%). In patients aged 40 years or older, affected by severe recurrent reflex syncope and tilt-induced asystole, dual-chamber pacemaker with CLS is highly effective in reducing the recurrences of syncope. Our findings support the inclusion of tilt testing as a useful method to select candidates for cardiac pacing. ClinicalTrials.gov identifier NCT02324920, Eudamed number CIV-05-013546., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/30868
Publicación Otros (Other)

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

  • Van Laethem, Jean-Luc
  • Geboes, Karen
  • Borbath, Ivan
  • Macarulla Mercade, Teresa
  • Lambert, Aurelien
  • Cassier, Philippe
  • Prenen, Hans
  • Mitry, Emmanuel
  • Blanc, Jean-Frederic
  • Pilla, Lorenzo
  • Feliu, Jaime
  • Rodriguez Garrote, Mercedes
  • Pazo-Cid, Roberto Antonio
  • Gallego, Inmaculada
  • Smith, Karin Enell
  • Nordbladh, Karin
  • Jimenez, David Gomez
  • Ellmark, Peter
  • Pico de Coaña, Yago
  • Ambarkhane, Sumeet Vijay
  • Beatty, Gregory L
  • O'Reilly, Eileen M
Response determinants to immunotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) remain unclear, limiting treatment advancements. We report a single-arm phase 1b/2 study (OPTIMIZE-1) evaluating the safety and efficacy of the cluster of differentiation 40 (CD40) agonist mitazalimab combined with modified FOLFIRINOX (mFOLFIRINOX), in chemotherapy-naive patients with mPDAC. Patients receive an initial dose of mitazalimab one week before starting biweekly cycles of mFOLFIRINOX plus mitazalimab. The study meets its pre-specified primary endpoint, achieving a confirmed objective response rate (ORR) of 42.1%. Median duration of response, progression-free survival, and overall survival was 12.6 months, 7.7 months, and 14.9 months, respectively. Multi-omic analyses of tumor and blood specimens identify a baseline tumor-intrinsic gene signature related to fibrosis associated with improved survival. Additionally, mitazalimab-induced increases in activated circulating myeloid, B cell, and T cell frequencies correlate with better outcomes. These results may inform future patient stratification strategies supporting a planned randomized confirmatory trial of mitazalimab with mFOLFIRINOX in mPDAC. This study was registered at ClinicalTrials.gov (NCT04888312)., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/13432
Publicación Otros (Other)

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

  • Garcia-Sanz, R
  • Sureda, A
  • Cruz, F-de-la
  • Canales, M
  • Gonzalez, A-P
  • Pinana, J-L
  • Rodriguez, A
  • Gutierrez, A
  • Domingo-Domenech, E
  • Sanchez-Gonzalez, B
  • Rodriguez, G
  • Lopez, J
  • Moreno, M
  • Rodriguez-Salazar, M-J
  • Jimenez-Cabrera, S
  • Caballero, M-D
  • Martinez, C
In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation (ASCT). This was a multicenter, open-label, phase I-II trial of patients with RRHL after first-line chemotherapy. Treatment had three 21-day cycles of etoposide, solumedrol, high-dose AraC, and cisplatin. BV was administered at three dose levels (0.9, 1.2, and 1.8 mg/kg) intravenous on day ‒1 to 3 + 3 cohorts of patients. Final BV dose was 1.8 mg/kg. Responding patients proceeded to ASCT, followed by three BV courses (1.8 mg/kg, every 21 days). Main end points for evaluation were maximum tolerable dose and overall and complete response (CR) before ASCT. A total of 66 patients were recruited (median age 36 years; range 18-66): 40 were primary refractory, 16 early relapse and 10 late relapse. There were 39 severe adverse events were reported in 22 patients, most frequently fever (n = 25, 35% neutropenic), including 3 deaths. Grade 3-4 hematological toxicity presented in 28 cases: neutropenia (n = 21), thrombocytopenia (n = 14), and anemia (n = 7). Grade ≥3-4 extrahematological adverse events (≥5%) were non-neutropenic fever (n = 13) and hypomagnesaemia (n = 3). Sixty-four patients underwent stem-cell mobilization; all collected >2×10e6/kg CD34+ cells (median 5.75; range 2.12-33.4). Overall response before transplant was 91% (CI 84% to 98%), including 70% (CRs 95% CI 59% to 81%). 60 patients were transplanted with no failure engraftments. Post-transplant response was CR in 49 patients (82% CI 73% to 91%) and partial responses in six (10% CI 5% to 15%). After a mean follow-up of 27 months, the 30-month time to treatment to failure was 74% (95% CI 68% to 80%), progression-free survival 71% (95% CI 65% to 77%), and overall survival 91% (CI 84% to 98%). BRESHAP looks a safe and effective pre-transplant induction regimen, does not jeopardize transplant and allows long-term remissions and survival., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/26962
Publicación Otros (Other)

Metabolomics of the tryptophan-kynurenine degradation pathway and risk of atrial fibrillation and heart failure: potential modification effect of Mediterranean diet.

  • Razquin, Cristina
  • Ruiz-Canela, Miguel
  • Toledo, Estefania
  • Hernández-Alonso, Pablo
  • Clish, Clary B
  • Guasch-Ferré, Marta
  • Li, Jun
  • Wittenbecher, Clemens
  • Dennis, Courtney
  • Alonso-Gómez, Angel
  • Fitó, Montse
  • Liang, Liming
  • Corella, Dolores
  • Gómez-Gracia, Enrique
  • Estruch, Ramon
  • Fiol, Miquel
  • Lapetra, Jose
  • Serra-Majem, Lluis
  • Ros, Emilio
  • Aros, Fernando
  • Salas-Salvadó, Jordi
  • Hu, Frank B
  • Martínez-González, Miguel A
The tryptophan-kynurenine pathway is linked to inflammation. We hypothesize that metabolites implicated in this pathway may be associated with the risk of heart failure (HF) or atrial fibrillation (AF) in a population at high risk of cardiovascular disease. We aimed to prospectively analyze the associations of kynurenine-related metabolites with the risk of HF and AF and to analyze a potential effect modification by the randomized interventions of the PREDIMED (Prevención con Dieta Mediterránea) trial with Mediterranean diet (MedDiet). Two case-control studies nested within the PREDIMED trial were designed. We selected 324 incident HF cases and 502 incident AF cases individually matched with ≤3 controls. Conditional logistic regression models were fitted. Interactions with the intervention were tested for each of the baseline plasma metabolites measured by LC-tandem MS. Higher baseline kynurenine:tryptophan ratio (OR for 1 SD: 1.20; 95% CI: 1.01, 1.43) and higher levels of kynurenic acid (OR: 1.19; 95% CI: 1.01, 1.40) were associated with HF. Quinolinic acid was associated with AF (OR: 1.15; 95% CI: 1.01, 1.32) and HF (OR: 1.25; 95% CI: 1.04, 1.49). The MedDiet intervention modified the positive associations of kynurenine (Pinteraction = 0.006), kynurenic acid (Pinteraction = 0.008), and quinolinic acid (Pinteraction = 0.033) with HF and the association between kynurenic acid and AF (Pinteraction = 0.02). We found that tryptophan-kynurenine pathway metabolites were prospectively associated with higher HF risk and to a lesser extent with AF risk. Moreover, an effect modification by MedDiet was observed for the association between plasma baseline kynurenine-related metabolites and the risk of HF, showing that the positive association of increased levels of these metabolites and HF was restricted to the control group., Sí
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/26965
Publicación Otros (Other)

A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial

  • Sanllorente, Albert
  • Soria-Florido, Maria Trinidad
  • Castaner, Olga
  • Lassale, Camille
  • Salas-Salvado, Jordi
  • Martinez-Gonzalez, Miguel Angel
  • Subirana, Isaac
  • Ros, Emilio
  • Corella, Dolores
  • Estruch, Ramon
  • Tinahones, Francisco J.
  • Hernaez, Alvaro
  • Fito, Montserrat
Background: Consumption of a Mediterranean diet, adequate levels of physical activity, and energy-restricted lifestyle interventions have been individually associated with improvements in HDL functions. Evidence of intensive interventions with calorie restriction and physical activity is, however, scarce. Objectives: To determine whether an intensive lifestyle intervention with an energy-restricted Mediterranean diet plus physical activity enhanced HDL function compared to a non-hypocaloric Mediterranean eating pattern without physical activity. Methods: In 391 older adults with metabolic syndrome (mean age, 65 years; mean BMI, 33.3 kg/m2) from 1 of the Prevención con Dieta Mediterránea-Plus trial centers, we evaluated the impact of a 6-month intervention with an energy-restricted Mediterranean diet plus physical activity (intensive lifestyle; n = 190) relative to a nonrestrictive Mediterranean diet without physical activity (control; n = 201) on a set of HDL functional traits. These included cholesterol efflux capacity, HDL oxidative/inflammatory index, HDL oxidation, and levels of complement component 3, serum amyloid A, sphingosine-1-phosphate, triglycerides, and apolipoproteins A-I, A-IV, C-III, and E in apoB-depleted plasma. Results: The intensive-lifestyle intervention participants displayed greater 6-month weight reductions (-3.83 kg; 95% CI: -4.57 to -3.09 kg) but no changes in HDL cholesterol compared with control-diet participants. Regarding HDL functional traits, the intensive lifestyle decreased triglyceride levels (-0.15 mg/g protein; 95% CI: -0.29 to -0.014 mg/g protein) and apoC-III (-0.11 mg/g protein; 95% CI: -0.18 to -0.026 mg/g protein) compared to the control diet, with weight loss being the essential mediator (proportions of mediation were 77.4% and 72.1% for triglycerides and apoC-III levels in HDL, respectively). Conclusions: In older adults with metabolic syndrome, an energy-restricted Mediterranean diet plus physical activity improved the HDL triglyceride metabolism compared with a nonrestrictive Mediterranean diet without physical activity. This trial is registered at isrctn.com as ISRCTN89898870., This work was supported by the Instituto de Salud Carlos III (grant numbers: CB06/03/0028, CD17/00122, IFI16/00012, PI15/00047, PI18/00020, and P19/00017), Fundació La Marató de TV3 (grant number: 201512.31), Agència de Gestió d’Ajuts Universitaris i de Recerca (grant number: 2017 BP 00021, 2017 SGR 222, SLT002/16/00088), and the European Regional Development Fund., Sí
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/29765
Publicación Otros (Other)

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

  • Hontecillas-Prieto, Lourdes
  • Garcia-Dominguez, Daniel-J
  • Palazon-Carrion, Natalia
  • Martin-Garcia-Sancho, Alejandro
  • Nogales-Fernandez, Esteban
  • Jimenez-Cortegana, Carlos
  • Sanchez-Leon, Maria-L
  • Silva-Romeiro, Silvia
  • Flores-Campos, Rocio
  • Carnicero-Gonzalez, Fernando
  • Rios-Herranz, Eduardo
  • Cruz-Vicente, Fatima-de-la
  • Rodriguez-Garcia, Guillermo
  • Fernandez-Alvarez, Ruben
  • Martinez-Banaclocha, Natividad
  • Guma-Padro, Josep
  • Gomez-Codina, Jose
  • Salar-Silvestre, Antonio
  • Rodriguez-Abreu, Delvys
  • Galvez-Carvajal, Laura
  • Labrador, Jorge
  • Guirado-Risueño, Maria
  • Provencio-Pulla, Mariano
  • Sanchez-Beato, Margarita
  • Marylene, Lejeune
  • Alvaro-Naranjo, Tomas
  • Casanova-Espinosa, Maria
  • Rueda-Dominguez, Antonio
  • Sanchez-Margalet, Victor
  • Cruz-Merino, Luis-de-la
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients. 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients. Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients. CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29., Si
Buscador avanzado